Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.76 |
| ▸ | CA12 | O43570 | 4/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.54 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4573383 | 0.93 | KEAP1 (0.76) | KEAP1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL407414 | 0.87 | KEAP1 (1.00) | KEAP1CA12CA9CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL3516799 | 0.85 | KEAP1 (0.96) | KEAP1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL18109243 | 0.83 | KEAP1 (0.71) | KEAP1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL12550095 | 0.80 | KEAP1 (0.79) | KEAP1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL27426675 | 0.80 | KEAP1 (0.66) | KEAP1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL27545286 | 0.80 | KEAP1 (0.61) | KEAP1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL5143984 | 0.79 | KEAP1 (0.76) | KEAP1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL198318 | 0.79 | CA12 (1.00) | KEAP1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL12793673 | 0.79 | KEAP1 (0.76) | KEAP1CA12CA9CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949567-B2 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1395548-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2003-06-26 | — | — | US | disclosed |
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2002-11-07 | — | — | US | disclosed |
| WO-2002070467-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | PKD2, PPOX, PKD1 | KEAP1 1374/4885CA12 3822/4885CA9 3193/4885 |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | CLIC1, PKD2, PKD1 | KEAP1 518/4885CA12 574/4885CA9 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.